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INTRODUCTION
Viruses are among the most important causes of infectious neurologic illness worldwide. 
Recent years have seen the control and near-elimination of neurologic illness due to some 
viruses, through advancements in community hygiene and public health, societal awareness 
of preventive measures, and, importantly, vaccines against many viral pathogens. However, 
these advances have been countered by the emergence and re-emergence of new viral 
infectious agents; spread of these emerging infectious diseases has been facilitated by 
increasing global movement and transport of people, animals, and materials, changes in 
agricultural practices, war and natural disasters, and closer contact between humans and 
animals, among other things. Thus, viral neurologic infections will continue to be a 
significant source of ongoing morbidity and mortality worldwide for the foreseeable future.
A fundamental component of understanding viral infections and infectious diseases in 
general is to define the epidemiology of the pathogen, including how it is transmitted and 
spread, and how it behaves within a population. An under standing of infectious disease 
epidemiology places illness in perspective among the population, and aids in assessing the 
impact of the disease. This chapter will first provide an overview of important concepts of 
infectious disease epidemiology, particularly as it pertains to neurologic illness, followed by 
an overview of important epidemiologic principles of specific neurologic syndromes 
associated with viral infections.
A brief overview of neuroepidemiology
Epidemiology is the study of health and illness and associated factors in populations. 
Epidemiology is essentially a science that assesses patterns of disease occurrence in human 
populations and the factors that influence these patterns (Lilienfeld and Stolley, 1994); the 
field of neuroepidemiology is simply the application of these epidemiologic principles to 
neurologic disorders. Epidemiologists are primarily interested in the occurrence of diseases 
as categorized by time, place, and person. Epidemiology attempts to determine whether 
there has been an increase or a decrease of disease over time, whether one geographic area 
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has a higher frequency of disease than another, and whether the characteristics of persons 
with a particular disease or condition distinguish them from those without it. The 
epidemiology of a disease is determined by the fundamental relationships among 
components of the epidemiologic triad – host, agent, and environment. Attributes of the 
host, such as age, gender, race, and occupation, often provide insight as to who is at risk for 
a disease and what exposures may contribute to that risk. Similarly, an under-standing of an 
agent’s biologic, physical, or chemical properties may help focus attention on some of the 
most likely explanations for disease. Finally, an understanding of where things happened 
can help identify environmental determinants such as the physical, biologic, social, and 
economic factors that may have allowed or promoted interaction between host and agent.
There are several features of neurologic disorders that present particular challenges to the 
traditional epidemiologic methods necessitating the specialized discipline of 
neuroepidemiology. Neurologic illnesses often progress and change clinical characteristics 
over time; thus, the likelihood of an accurate diagnosis may be greater in persons with 
advanced illness, potentially leading to over- or underestimation of cases if evaluated early. 
Often, the actual timing of onset of a neurologic disease is not known, which may make 
determination of risk factors difficult. Persons with neurologic disorders may have altered 
mental status or memory deficits, making recall of past events and potential risk factors 
problematic. Finally, many neurologic illnesses are syndromes in which diagnosis rests upon 
an accurate interpretation of a constellation of physical and neurologic signs and symptoms, 
rather than diagnostic tests. This increases the potential risk of misclassification of cases.
Basic epidemiologic terms and concepts (Lilienfeld and Stolley, 1994)—The 
fundamental activity of the epidemiologist is counting – the fundamental method of 
determining the extent of a health event affecting a population is to count cases. It is very 
important to define what a “case” is, and a case definition must be created. As simple as it 
may appear, that is not always easy, particularly in the setting of an epidemiologic 
investigation of an unknown illness. Once the definition of a case is determined, the number 
of such cases must be assessed in light of the population from which they are obtained. 
Rates are measures for relating cases to the population; with rate information, it is possible 
to determine whether one group or another is at increased risk of disease, and by how much. 
The most commonly used measures of rates are incidence, attack rate, and prevalence.
Incidence or incidence rate measures the risk of new cases occurring in a population over a 
defined period of time. The numerator is the number of new cases, and the denominator is 
the population at risk during the specified time period:
An attack rate is the proportion of a defined population that develops a disease usually over 
the course of an outbreak. Attack rate is often expressed as a percentage.
Prevalence is the proportion of the population that has a disease at a given time. These 
measures are functions of both the disease incidence and disease duration:
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Risk factors are attributes of the agent, host, and environment that increase the risk of a 
disease. Protective factors are attributes of the agent, host, and environment that decrease 
risk of the disease. Assessment of risk and protective factors involves the comparison of 
frequency of disease in a group exposed to those factors with disease frequency in the 
unexposed group. The relative risk (RR) is the ratio of risk of disease among persons in an 
exposed population to that in an unexposed population. RRs best reflect the effect of an 
exposure of interest when the groups being compared are similar in all variables being 
evaluated that might alter the RR except for the exposure of interest or when the RRs are 
adjusted to account for the known differences in these variables. An RR of 1.0 indicates 
identical risk in the compared groups; an RR greater than 1.0 indicates that those with the 
exposure have a higher risk than those without, and an RR less than 1.0 indicates the 
opposite – that those with the exposure have a lower risk than those without. It is important 
to differentiate the RR from the attributable risk (AR) – the absolute amount of risk directly 
due to exposure. AR is estimated from the difference between the risk of developing a 
disease in the exposed and unexposed groups. An AR of zero means that there is no 
difference in risk of disease between the exposed and unexposed groups.
Pragmatically, in epidemiologic studies it is often useful to compare risk factors by looking 
at odds. The concept of odds is slightly different from that of risk, and is used when the total 
number of persons who may have been exposed to a situation or agent is not actually known, 
as is frequently the case in epidemiologic investigations. The odds of an event occurring is 
the probability that the event will occur divided by the probability that the event will not 
occur. Odds compare the number of ill persons known to be exposed to a particular factor to 
the number of non-ill persons known to be exposed to that factor:
By knowing the odds, one can then calculate an odds ratio, which compares the odds in 
those exposed to the factor to the odds in those not exposed; the odds ratio is essentially an 
equivalent of an RR when the illness is rare in the population under study.
In the setting of an outbreak, it is useful to assess the number of cases occurring over time, 
which is generally graphed with a histogram (Gregg, 1996). If the time period of interest 
represents the duration of the outbreak, the histogram is referred to as an epidemiologic 
curve (Fig. 3.1). The number of cases is specified on the y axis, while the time intervals are 
represented on the x axis. Such epidemiologic curves may be constructed in ways that 
stratify case groups by certain variables, such as place (residence, employment) or by 
personal characteristics (age, gender, race). Incidence rates of disease over time, on the other 
hand, are generally plotted using a line graph, with the x axis representing the period of time 
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of interest, and the y axis representing the incidence rate of the health event per unit 
population (usually per 1000 or per 100 000).
Epidemiologic studies (Lilienfeld and Stolley, 1994)—There are a number of 
different epidemiologic methods that are used to assess and characterize diseases. Disease 
surveillance is an ongoing process which involves the systematic collection, analysis, 
interpretation, and dissemination of reports on the occurrence of disease within a defined 
population; surveillance is a key component of public health activities (Teutsch and 
Churchill, 1994). Surveillance for disease can be conducted on a number of different levels, 
such as community-based surveillance, hospital-based surveillance, or national surveillance. 
Syndromic surveillance, which assesses the occurrence of constellations of clinical features, 
is often used. Surveillance for disease may be either active or passive. Active surveillance 
utilizes a regular, systematic method to proactively contact reporting sources, review 
medical records, or otherwise identify cases to assess the occurrence of disease. Passive 
surveillance relies on the individual clinician, laboratory, or hospital initiating the report of 
the illness. Unlike with active surveillance, the absence of reported cases in passive 
surveillance may reflect failures to report rather than absence of identified cases. Active 
surveillance tends to provide more complete, timely, and accurate data, but is often more 
resource-intensive. Passive surveillance is often less resource-dependent and easy to 
implement, but may be less sensitive or complete in case ascertainment.
The two most frequently used study approaches in epidemiologic analysis include cohort 
and case-control studies. Choice of these study designs is generally dictated by several 
factors, including the particular study question; the exposure frequency; the prevalence or 
incidence of the illness; and logistics. In a cohort study, subjects are classified on the basis 
of presence or absence of exposure to a particular factor, and then followed in time to assess 
the development of disease. Cohort studies may be either prospective (following subjects 
actively forward in time) or retrospective (where the outcome of interest has already 
occurred, and all of the follow-up has occurred in the past and all information is historical). 
Cohort studies are most useful to study common outcomes that may occur within short 
periods of time, or to study outcomes following a rare exposure. Cohort studies are useful in 
documenting the natural history of disease, and identifying particular risk factors for 
illnesses; population-based cohort studies may allow for determining incidence and 
prevalence of a disease.
The second main epidemiologic study approach is the case-control study. In case-control 
studies, subjects with the outcome of interest are identified, and the exposure history is 
compared with a group (controls) who do not have the outcome of interest. Case-control 
studies are most useful in studying diseases that are uncommon or have a long period 
between exposure and development of disease. Case-control studies may be subject to 
selection bias, since the association is being studied after exposure and disease have already 
occurred, and subjects are selected on the basis of having the outcome of interest. Case-
control studies often involve matching, in which the cases and controls are made as similar 
as possible based upon various variables (age, sex, occupation) so as to highlight the 
particular risk factors that might result in disease in some and not in others. Matching of one 
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case with more than one control (e.g., 1:2 matching, 1:4 matching) is often done to increase 
the power or ability to detect a statistically significant difference between cases and controls.
Another category of epidemiologic assessment is the outbreak investigation. This type of 
assessment is often employed by public health personnel and combines several different 
epidemiologic methods. This method is used to investigate apparent sudden increases in 
numbers of cases of illness over particular periods of time, and is often initiated rapidly. 
Outbreak investigations may involve several concurrent epidemiologic methods, including 
surveillance, case series, case-control, and cohort studies. Each of these may be conducted in 
parallel or sequentially, depending upon the situation. Laboratory testing of biologic or 
environmental specimens, for etiologic confirmation, is often a critical component of 
outbreak investigations. The ultimate goals of an outbreak investigation are to determine the 
cause / etiology, and implement control measures in order to control and prevent further 
disease (Reingold, 1998).
When interpreting results of epidemiologic studies, it is important to question whether an 
observed association between an exposure and outcome reflects a true cause-and-effect 
relationship, or if it is occurring by chance alone; this is generally determined by various 
statistical tests. The association can also be the result of bias or by confounding. Bias 
represents a systematic error in an epidemiologic study that results in an incorrect estimate 
of the association between exposure and risk of disease. There are several types of bias, 
including selection bias, in which subjects chosen for a study differ from those who would 
otherwise be eligible but were not included; and information bias, in which there is a 
systematic error in the measurement of data on exposure or outcome. For example, if we 
were to compare the incidence of transverse myelitis (TM) in the United States with that in 
certain African countries, we might find that TM is far more common in the United States. 
This may be reflective of a true higher incidence of TM in this setting; however, it may also 
reflect the fact that advanced diagnostic testing such as magnetic resonance imaging is more 
widely available in the United States, whereas in Africa the diagnosis is made by neurologic 
exam alone, which may be less sensitive.
Misclassification, a type of information bias, results when there is an inaccurate assessment 
of exposure and/or disease status. For example, if disease status is inaccurately determined, 
this can result in surreptitious findings. This is particularly true in various neurologic 
disorders, such as Alzheimer’s disease, Parkinson’s disease, or amyotrophic lateral sclerosis, 
in which illness can be present long before it is clinically apparent, diagnosis is based on a 
constellation of signs and symptoms, and the validity of a diagnosis may depend upon the 
clinical skill of the examiner.
Recall bias occurs when subjects with and without outcome of interest report exposures 
differently. Oftentimes, cases may recall particular events with more clarity than controls, if 
they feel that particular exposures may have been associated with their illness. In neurologic 
diseases, cognition is often impaired, there may be difficulty in assessing the validity of 
exposure history, or history may rely upon information provided by a proxy, who may not 
have all possible exposure information available.
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Confounding occurs when an observed association is due, partially or totally, to the effects 
of differences between the cases and controls other than the exposure under assessment, 
which could affect their risk of developing the outcome of interest. It occurs when another 
factor is associated with both the exposure of interest and the risk of developing the disease 
and may account for some or all of the association between exposure and disease. 
Confounding maybe reduced, again, by matching for variables that may be associated with 
exposure and outcome.
The cornerstone of all epidemiologic analyses is the 2×2 table (“two-by-two table”), which 
is often the first analysis performed when looking at epidemiologic data. The basic 2×2 table 
(for a case-control study) appears as such:
Exposed Not exposed
Cases a b a + b
Controls c d c + d
a + c b + d Total
where:
a = number of ill people exposed to a factor
c = number of well people exposed to a factor
b = number of ill people not exposed to a factor
d = number of well people who were not exposed
a + b = total number of cases
c + d = total number of controls
a + c = total number who were exposed
b + d = total number who were not exposed
For instance, presume that a group of people at a party consume a particular appetizer; the 
following day, a number of them develop severe headaches. You would like to know if 
consuming the appetizer was associated with the headaches. We can try to calculate the odds 
of the appetizer being associated with the headaches in this group. Let’s say a total of 94 





Headaches 6 31 37
No headaches 9 48 57
Total 15 79 94
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The odds of headaches in those eating the appetizer is 6/9 = 0.67, while the odds of 
headaches in those not eating is 31/48 = 0.65. Thus, the odds ratio for headaches following 
the appetizer is 0.67/0.65=1.03. Thus there would appear to be a nearly equal chance of 
developing a headache, whether the appetizer was consumed or not.
Additional statistical methods are needed to further assess significance, and to analyze more 
complex data sets; however, the 2×2 table is an effective and simple method of assessing 
basic epidemiologic data.
EPIDEMIOLOGY OF VIRAL INFECTIONS OF THE NERVOUS SYSTEM
Mechanisms of viral-mediated neurologic disease
Viruses may lead to nervous system disorders in multiple ways (Johnson, 1998). They may 
directly infect and replicate within nerve cells, leading to neural inflammation, necrosis, and 
damage (“neuroinvasive disease”), as is the case with viral encephalitis and myelitis. They 
may cause infection and inflammation limited to the meninges, leading to aseptic 
meningitis. In some cases, viruses may serve as an antigenic stimulus to the immune system 
and produce an indirect, immune-mediated attack on the central or peripheral nervous 
system, as is the case in acute inflammatory demyelinating polyradiculoneuropathy or acute 
disseminated encephalomyelitis (Hughes et al., 1999; Young et al., 2008). In rare cases, 
viruses may produce latent or persistent infections within nerve cells, resulting in episodic 
recurrences of clinical illness (e.g., herpes zoster with varicella-zoster virus (VZV)) (Guess 
et al., 1986), or progressive neurodegenerative illness (subacute sclerosing panencephalitis 
(SSPE) following measles infection) (Gutierrez et al., 2010). Some viruses may be acquired 
congenitally and result in developmental neurologic illness (e.g., congenital 
cytomegalovirus and rubella neurodevelopmental disorders) (Bale and Murph, 1992; 
Griffith and Booss, 1994). Some viral infections may initiate a vasculitis, producing central 
nervous system (CNS) effects through brain infarcts or focal neurologic deficits (Nagel et 
al., 2008). In some cases, a combination of specific host factors and an infecting virus may 
produce indirect neurologic disease: this is the case for Reye syndrome that occurs shortly 
after salicylate treatment of children with various viral illnesses, particularly influenza and 
varicella-zoster infection (Glasgow and Middleton, 2001). Although not the case for viruses, 
some infectious agents elaborate neurotoxins that can result in neurologic disease, as is the 
case for tetanus and dipththeria toxins produced by the bacteria Clostridium tetani and 
Corynebacterium diphtheriae, respectively. Finally, other end-organ damage from a viral 
infection may produce a concomitant neurologic illness indirectly (e.g., encephalopathy in 
the setting of viral hepatitis-associated liver failure). Neurologic illness with any particular 
virus may be a result of one or several of these mechanisms. The epidemiology of viral-
associated neurologic illness is in part influenced by which of the mechanisms above is 
associated with a particular virus.
Factors influencing the epidemiology of viral CNS disease
There are several key factors that influence the epidemiology of viral infections of the 
nervous system. Of critical importance is the host–agent relationship, which is dependent 
upon various features and characteristics of both the infecting agent, as well as the particular 
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properties or characteristics of the person who is infected (host) (Mandell et al., 2005). Both 
of these factors influence the occurrence and pattern of human infections, and need to be 
considered in tandem. Various features of the infecting agent may influence the occurrence 
of disease (Mandell et al., 2005). Infectiousness describes the relative ease or difficulty by 
which an agent may be transmitted to other hosts; respiratory or droplet-spread agents tend 
to be more infectious than those spread by close person-to-person contact, for instance. 
Infectivity relates to the ability of an infectious agent to enter, survive, and multiply in a 
host, and is generally estimated by assessing the number of hosts infected in the context of 
the number of susceptible and exposed individuals. Pathogenicity is the ability of an agent to 
cause clinical disease in a host once infection occurs; although this is in large part related to 
specific characteristics of the infectious agent, host susceptibility may also play a large role 
in pathogenicity. Similarly, virulence refers to the relative severity of infection caused by a 
pathogenic agent, and refers to the numbers of serious or disability-producing infections 
compared to the total number of infected persons. Immunogenicity is the ability of an 
infecting agent to stimulate an immunologic response in the host; this in part determines the 
pathogenicity and virulence of a particular agent, and is an important determinant of whether 
infection confers long-lasting immunity to the agent. Nearly all of these agent factors are 
substantially influenced by concomitant host factors. For instance, the pathogenicity of a 
particular agent may be greatly increased in persons with particular risk factors, such as 
weakened immunity or extremes of age. The virulence of a particular agent may similarly be 
influenced by particular host risk factors.
Another important influential determinant of virus epidemiology is the route of 
transmission; this is the pathway by which an infectious agent is spread through the 
environment or to another person (Mandell et al., 2005). Direct-contact spread involves 
passing an infectious agent directly from one person to another by way of respiratory 
droplets, touching, kissing, or sexual intercourse, or by exposure of susceptible tissue to the 
agent, for instance through a rabid animal bite. Indirect transmission includes vehicle, 
vector-borne, and air-borne transmission. Vehicle transmission involves a material that 
serves as an intermediate by which an infectious agent can gain access to the host, for 
instance by food, water, biological tissues (blood, urine), or objects (fomites). Vector-borne 
infections are spread when an insect vector transmits an infectious agent mechanically, as in 
a bite, directly to the host. Air-borne transmission occurs when aerosols containing 
infectious agents disseminate to a host and gain entry to the host through some portal, 
generally the respiratory tract. Air-borne transmission requires infectious particles to be 1–5 
µm in diameter, smaller than respiratory droplets (Polymenakou et al., 2008).
There are various epidemiologic patterns associated with viral neurologic infections. Some 
viral infections result in sporadic cases of neurologic disease, with no specific temporal or 
geographic pattern. Infections may also have an endemic pattern, in which cases of illness 
predictably occur among members of the population at a certain frequency. In some cases, 
infections may result in regular, predictable seasonal increases in numbers of cases, due to 
various geoclimactic or population factors. Others may result in epidemics, in which large 
numbers of cases of illness occur in a particular geographic area and over a specific period 
of time; these epidemics may occur on a predictable basis, but more commonly occur in an 
unpredictable fashion. An epidemic occurring within a large geographic area, typically 
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affecting many countries in multiple continents, is referred to as a pandemic. Following a 
certain period of time, an infectious agent that initially resulted in epidemic disease may 
become endemic in a population (e.g., occurring regularly within the native population); this 
shift from epidemic to endemic disease has most recently been demonstrated by West Nile 
virus (WNV) in the United States.
Epidemiology of viral neurologic infections (Table 3.1)
Encephalitis—Encephalitis is defined as an acute or subacute cerebral inflammatory 
condition (Sejvar et al., 2011). Clinically, it is characterized by the acute onset of headache, 
encephalopathy or alteration of mental status, focal neurologic signs, and seizures. 
Cerebrospinal fluid (CSF) is characterized by moderate pleocytosis and protein elevation. 
There are many different etiologies that may lead to encephalitis, including toxic agents, 
neoplastic causes, and immune-mediated disorders; however, the most commonly identified 
causes of encephalitis are infectious agents, particularly viruses. In many cases, however, a 
definitive underlying etiology for encephalitis can be elusive; even with extensive testing for 
infectious or chemical etiologies, up to 60% of cases of encephalitis remain without a 
definitive underlying etiology (Glaser et al., 2003; Granerod et al., 2010). This likely attests 
to both the wide range of potential infectious pathogens, toxic substances, and 
environmental factors that may result in encephalitis, as well as limitations on the sensitivity 
and repertoire of laboratory testing currently available to identify potential etiologies.
The epidemiology of encephalitis is complex, and estimates of incidence rates vary widely. 
This is due in part to differences in case definitions between studies, differences in 
diagnostic capabilities, and geographic location in which studies have been conducted. Most 
studies of encephalitis have been hospital-based, and assess endemic disease. Estimated 
overall rates among all ages have been between 1 and 6 cases /100 000 persons per year in 
most hospital-based studies (Klemola et al., 1965; Ponka and Pettersson, 1982; 
Radhakrishnan et al., 1987); one population-based study estimated an incidence of 7.4 
cases / 100 000 persons per year (Nicolosi et al., 1986). Most studies suggest that 
encephalitis is more frequently observed in younger persons; in children and adolescents, 
incidence estimates range from 1 to 16 cases per 100 000 per year in children (Rantakallio et 
al., 1986; Koskiniemi et al., 1991). It is important to keep in mind that most studies of the 
incidence and epidemiology of encephalitis have been conducted in industrialized countries, 
and that the epidemiology of encephalitis in the developing world is less well described. 
Case fatality rates and estimates of neurologic sequelae also vary, depending upon study 
methods and underlying etiologic agent. Population- and hospital-based estimates of 
neurologic sequelae following encephalitis have ranged from 0.35 to 2.7 per 100000 
population (Koskiniemi et al., 1991; Rantala et al., 1991; Sejvar et al., 2008a), with case 
fatality rates ranging from 1% to 10% (Rautonen et al., 1991). However, certain agents are 
associated with higher case fatality rates; mortality of up to 33% has been reported with 
herpes simplex encephalitis (HSE) (Skoldenberg and Forsgren, 1985).
The etiology and epidemiology of viral encephalitis will vary based upon a number of 
variables, including age group affected, geographic location, and underlying immune status 
of affected individuals. Some viruses lead to sporadic cases of encephalitis. This is 
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particularly true in the case of alpha-herpesviruses, which include herpes simplex virus-1 
(HSV-1), HSV-2, and VZV. Herpesviruses are double-stranded DNA viruses and are 
ubiquitous throughout the world (Skoldenberg, 1996; Hjalmarsson et al., 2007; Steiner et al., 
2007). HSV-1 is the most common cause of identified sporadic viral encephalitis worldwide, 
and in the United States accounts for 20% of all cases with a defined etiology, with an 
incidence of approximately 2 cases per million population (Steiner et al., 2007). HSV-2 
more typically produces genital cutaneous lesions, but may also cause encephalitis, 
accounting for approximately 5% of HSE overall (Johnson, 1998). Less commonly, it may 
result in aseptic meningitis. HSE occurs worldwide and throughout the year, with no 
seasonal variation. Spread of the virus is through direct close contact, and HSV-1 infection 
is influenced by socioeconomic factors, with lower socioeconomic status associated with 
earlier and more frequent infection (Skoldenberg, 1996). The age distribution of HSE 
appears to be bimodal, with peaks at ages 5–30 years, and then over 50 years. Currently, 
specific risk factors for the development of HSE are not known.
VZV is the third member of the alpha-herpesvirus group. Primary infection with VZV 
results in a febrile rash illness with a vesicular exanthema (“chickenpox” or varicella). 
Susceptible individuals become infected through respiratory exposure, and VZV is highly 
infectious, with attack rates among susceptible household contacts of over 80%. Although 
predominantly a febrile rash illness, neurologic disease with varicella is not uncommon, 
with the overall incidence of CNS disease estimated to be 1–3/10 000 clinical cases (Guess 
et al., 1986). The most commonly reported CNS manifestations are acute encephalitis and 
cerebellar ataxia. Encephalitis may occur in approximately 1–2 per 10 000 cases of clinical 
varicella (Choo et al., 1995); although most total varicella cases occur in children, incidence 
of neurologic disease associated with varicella illness is highest in adults over age 20, and 
infants <1 year (Guess et al., 1986). Cerebellar ataxia is somewhat more common, affecting 
approximately 1 in 4000 cases (Guess et al., 1986). Case fatality from varicella encephalitis 
varies considerably, ranging from 5% to 35%, and long-term sequelae may be seen in 10–
20% of survivors (Guess et al., 1986).
More commonly, viral encephalitis occurs in epidemics, in which a large number of cases 
occur in a geographically and temporally clustered fashion. Enteroviral infections, while 
more commonly associated with aseptic meningitis (see below), may result in seasonal 
epidemics of viral encephalitis in temperate areas. Enteroviruses have a world wide 
distribution, and may produce endemic viral encephalitis, or large outbreaks of encephalitis 
affecting large populations. Recently, large outbreaks of enterovirus-71-associated illness 
have occurred and resulted in large numbers of cases of severe neurologic illness, primarily 
in children (Solomon et al., 2010). Arthropod-borne viruses (arboviruses) are among the 
most common causes of epidemic encephalitis worldwide (Gubler, 2001). Arboviruses refer 
to a class of viruses that are transmitted by arthropod vectors, generally mosquitoes or ticks 
(Calisher, 1994; Gubler, 2001). They all have complex life cycles involving enzootic 
transmission between vertebrate and invertebrate hosts, which allows for the virus to 
become increasingly prevalent in the environment (amplification). Humans become infected 
following the bite of an infected arthropod vector. While most human infections with 
arboviruses result in clinically silent illness or mild febrile illness, more severe 
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manifestations, including hemorrhagic fever, aseptic meningitis, and encephalitis, may 
result.
There are over 20 arboviruses recognized to cause encephalitis, constituting several different 
viral families (Gubler, 2002). Most arboviruses produce endemic illness with periodic large 
outbreaks; these outbreaks are dependent upon a complex interaction of geoclimactic factors 
that favor increased populations of arthropod vectors, sufficient populations of amplifying 
hosts, and susceptible human populations. For instance, St. Louis encephalitis virus, a 
mosquito-borne flavivirus found in North America and, to a limited extent, South America, 
results in sporadic cases of encephalitis yearly, predominantly in late summer or fall. 
However, periodic focal outbreaks involving hundreds of cases have occurred at intervals in 
various regions of the United States (Luby et al., 1969; Zweighaft et al., 1979). Japanese 
encephalitis virus (JEV), another flavivirus transmitted by mosquito vectors, is the most 
important cause of encephalitis throughout Asia (Misra and Kalita, 2010). In areas with 
endemic transmission, incidence of Japanese encephalitis in children aged <15 years is 
approximately 2.5/100 000 population, with case fatality estimated at 25% (Solomon et al., 
2000). However, in temperate areas, Japanese encephalitis may result in frequent and large 
epidemics, with attack rates of up to 20 cases per 100 000.
The emergence of a pathogen into a new setting, by importation or geographic spread, may 
initially result in large epidemics; over time, the pathogen may then become endemic in this 
new region. An example of this shift from epidemic to endemic disease has been the 
epidemiologic pattern of WNV in North America. WNV, an arbovirus of the flavivirus 
family, was first identified in North America in 1999, and by 2002, resulted in an explosive 
epidemic of encephalitis covering much of continental United States and parts of Canada 
(Granwehr et al., 2004; Kramer et al., 2007). By 2006, however, case counts declined, and in 
subsequent years, WNV appears to have become endemic in various parts of the United 
States (Centers for Disease Control and Prevention). The possibility of subsequent large 
outbreaks, however, cannot be excluded.
Aseptic meningitis
Aseptic meningitis is commonly defined as a syndrome consisting of acute onset of 
meningeal signs and symptoms, CSF pleocytosis, and absence of microorganisms on Gram 
stain or culture (Tapiainen et al., 2007). Clinically, aseptic meningitis presents with the 
abrupt onset of fever, headache, and meningeal signs, including nuchal rigidity, photo- or 
phonophobia, and nausea/vomiting. CSF is characterized by a moderate pleocytosis and 
elevation in protein, but negative bacterial studies. It is characterized by a relatively benign 
clinical course, and the absence of features of encephalitis or myelitis. Like encephalitis, 
there are numerous etiologies of aseptic meningitis, including toxic, immune-mediated, 
neoplastic, and chemical causes, as well as a host of infectious pathogens. However, the 
most common causes of aseptic meningitis are viral etiologies (Tapiainen et al., 2007).
The various epidemiologic features described for encephalitis are largely true for aseptic 
meningitis as well. Despite advanced testing, a large proportion of cases remain without a 
definitive identified etiology. Most cases are sporadic or endemic, which may or may not 
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have a regular expected seasonal fluctuation, with some pathogens associated with epidemic 
disease.
Although there are a number of different viral etiologies of aseptic meningitis, the most 
important cause worldwide of aseptic meningitis are the enteroviruses, with non-poliovirus 
enteroviruses accounting for up to 90% of all cases of aseptic meningitis in which an 
etiologic agent is detected (Tapiainen et al., 2007). Enteroviruses are made up of over 70 
different serotypes within the family Picornaviridae, and many of these different serotypes 
may result in aseptic meningitis. Enteroviruses are distributed worldwide, and the 
epidemiologic pattern varies with geographic location. In temperate areas, enteroviral 
infections occur with a distinct summer / fall seasonal distribution; in tropical and 
subtropical areas, there is a higher year-round incidence of infection. Enteroviruses are 
spread from person to person by a fecal–oral route; transmission may also occur through the 
respiratory route, usually through direct contact with nose and throat discharges or through 
aerosol droplets or through contaminated food or water (Lee and Davies, 2007). Humans are 
thought to be the only natural reservoir of enteroviruses (Mandell et al., 2005). While there 
are many different serotypes of enteroviruses that may result in aseptic meningitis, in any 
particular geographic location infection is generally dominated by only a few of these 
serotypes (Glass et al., 2001). It appears that certain enterovirus serotypes are more 
commonly associated with aseptic meningitis.
Population-based estimates in the United States have suggested an overall incidence of 
aseptic meningitis of 10/100 000 persons among all ages (Beghi et al., 1984). Children are 
most likely to develop aseptic meningitis; estimates in Finland suggest an annual incidence 
of viral meningitis of 219/100 000 population in children less than 1 year of age (Rantakallio 
et al., 1986); this incidence dropped to 19/100 000 population in children between 1 and 4 
years, and continued to decline with increasing age. Similar findings suggesting higher 
childhood incidence have been obtained by other studies (Khetsuriani et al., 2003, 2006; Lee 
et al., 2005; Lee and Davies, 2007).
Some viruses more commonly associated with more severe CNS infection may also result in 
endemic or epidemic aseptic meningitis. Arboviruses, in addition to causing endemic and 
epidemic encephalitis, may cause aseptic meningitis, particularly in older persons (Calisher, 
1994). Herpesviruses, while more commonly associated with encephalitis, may result in 
aseptic meningitis as well (Skoldenberg, 1996).
Anterior myelitis
Anterior myelitis is the most common cause of acute flaccid paralysis worldwide. It is a 
syndrome characterized by acute, areflexic limb weakness or paralysis due to viral damage 
to the anterior horn cells or lower motor neurons of the spinal cord. Prior to the advent of 
vaccination, far and away the most common cause of anterior myelitis was infection with 
poliovirus, a small enterovirus of the family Picornaviridae (Mandell et al., 2005). 
Poliovirus has historically been so strongly associated with the syndrome of anterior 
myelitis that the term “poliomyelitis” has become synonymous with the syndrome. There 
are, however, a number of other viruses that are important causes of anterior myelitis, 
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including some other enteroviruses, arboviruses, and herpesviruses (Solomon and Willison, 
2003).
The epidemiology of poliovirus anterior myelitis has undergone significant changes in the 
past decades. The syndrome has been recognized for centuries; however, detailed 
descriptions of the clinical illness did not begin to appear until the 1700 s. Until the late 19th 
century, poliomyelitis was only associated with sporadic cases of acute limb weakness 
(Nathanson and Kew, 2010). However, beginning in the late 1800 s, large summertime 
outbreaks of poliomyelitis began occurring in northern Europe and the United States 
(Mandell et al., 2005). This shift from sporadic disease to large epidemics has largely been 
attributed to improved hygiene in these areas, which resulted in lack of exposure to the virus 
in infancy. Exposure in early childhood generally produced mild infections due to the 
presence of passively acquired maternal antibody; these mild infections, however, resulted 
in the development of inherent immunity, affording ongoing protection. Infections later in 
life result in more severe neurotropic disease, thus leading to increasing burden from 
poliovirus infections (Nathanson and Kew, 2010).
Following the recognition in the early 1900s that the cause of poliomyelitis was a small 
enterovirus, and that there were three different serotypes of poliovirus, successful production 
of both an inactivated (killed) polio vaccine and a live attenuated oral poliovirus vaccine 
was possible. Development and implementation of these effective poliovirus vaccines had a 
dramatic effect on epidemic poliomyelitis. In the United States, attack rates of poliomyelitis 
decreased from over 17 cases per 100 000 population in 1955 to 0.4 cases per 100 000 
population in 1962 (Nathanson and Kew, 2010). By 1994, the World Health Organization 
declared the Americas as “polio free” (Fig. 3.2) (Alexander et al., 2004).
Even after the introduction of polio vaccine, poliomyelitis was widely regarded as an 
epidemic disease of the developed world, and largely ignored in developing countries. 
However, acute flaccid paralysis surveillance during the 1960s and 1970s suggested that the 
prevalence of limb paralysis, mostly attributable to poliovirus infection, in populations of 
the developing world was between 2 and 11/1000 population (Henderson, 1984), a rate 
exceeding that of poliomyelitis in peak epidemic years in the United States. Most cases of 
poliomyelitis in developing countries occur in young children between 6 months and 2 
years. Because poliomyelitis in developing countries is largely endemic rather than 
epidemic, and there is a high incidence of other causes of severe physical disabilities in 
these areas, poliomyelitis had received less public concern. However, beginning in 1974, the 
World Health Organization began making concerted efforts toward the worldwide control of 
vaccine-preventable infectious diseases, including poliomyelitis. By 2002, fewer than 1900 
cases of poliomyelitis were reported worldwide, strictly among a handful of countries in 
sub-Saharan Africa, the Middle East, and south Asia (Centers for Disease Control and 
Prevention, 2009a). However, in recent years, there have been several setbacks in this goal, 
with several large outbreaks of poliomyelitis occurring in Tajikistan, the Republic of Congo, 
and elsewhere. Such setbacks have been due to a variety of problems, including a less 
developed infrastructure in developing countries contributing to limitations in both the 
effectiveness of the oral poliovirus vaccines themselves (e.g., more potentially interfering 
enteric viruses in recipients) and to decreased capacity to implement the multiple 
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vaccination campaigns required to maintain high population levels of immunity (Centers for 
Disease Control and Prevention, 2009b). New strategies are not being introduced to reach 
the elusive goal of poliomyelitis eradication.
As poliovirus poliomyelitis has been controlled in much of the developed and developing 
world, however, other causes of infectious myelitis have become increasingly recognized. 
Other non-poliovirus enteroviruses, in particular coxsackie A and B viruses (Santhanam and 
Choudhury, 1985; Jiang et al., 2007; Dhole et al., 2009), have been associated with sporadic 
cases of pediatric and adult anterior myelitis. Cases of anterior myelitis have occurred in 
several notable large outbreaks of enterovirus-71 in Malaysia, Taiwan, and other Asian 
countries (Solomon et al., 2010), although the usual neurologic complication of this virus is 
acute encephalitis. Arthropod-borne flaviviruses have recently emerged as an important 
cause of infectious myelitis, with large outbreaks of Japanese encephalitis associated with 
cases of myelitis in endemic and epidemic regions (Solomon and Vaughn, 2002; Solomon 
and Willison, 2003); during the North American WNV epidemic, incidence of WNV 
myelitis was estimated to be up to 3.7/100 000 population (Sejvar et al., 2005). 
Herpesviruses, particularly VZV and HSV-1, have been associated with sporadic cases of 
myelitis worldwide (Guess et al., 1986). The incidence of these other causes of infectious 
myelitis does not approach those historically seen for poliovirus infection, however, and 
fortunately the ongoing control of poliovirus infection through vaccination has resulted in a 
continued dramatic decline in infectious myelitis worldwide.
Myelopathy—In addition to anterior myelitis, several viruses may be associated with a 
more diffuse myelopathy or myeloneuropathy. This is particularly true for several 
retroviruses, including human T-cell lymphotrophic virus (HTLV), types I and II, and 
human immunodeficiency virus (HIV). HTLV-I infection is associated with adult T-cell 
leukemia; however, it also may cause tropical spastic paraparesis (TSP) and HTLV-I-
associated myelopathy (HAM) (Araujo and Silva, 2006; Cooper et al., 2009). HTLV-I has a 
worldwide distribution, but has focal concentrations in certain populations; seroprevalence 
for the virus is particularly high in certain districts in Japan and in the Caribbean (Araujo 
and Silva, 2006). The virus is transmitted primarily through sexual contact, contaminated 
blood, or perinatally through breast milk. Onset of TSP-HAM is most frequent in the fourth 
and fifth decades, although younger ages of onset may occur, and it is more common in 
females. The onset of illness is slow and progressive, with the development of backache, leg 
stiffness, and dysesthesias, as well as weakness, spasticity, hyperreflexia, and extensor 
plantar responses. Upper extremities are generally spared. Sensory loss, particularly to 
vibration and position sense, may occur, and in some cases a concomitant peripheral 
neuropathy may develop (Grindstaff and Gruener, 2005). The illness is generally 
progressive, leading to gait difficulties. An illness resembling TSP-HAM has been observed 
with infection with HTLV-II, which appears to be particularly prevalent among Native 
Americans (Roucoux and Murphy, 2004). Among the various neurologic manifestations that 
it may cause, HIV can be associated with a progressive vacuolar myelopathy (Berger and 
Sabet, 2002). Herpesviruses and enteroviruses can also uncommonly be associated with 
myelopathy (Berger and Sabet, 2002).
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Chronic viral CNS infections/prion disease
A group of CNS viral infections have been recognized as having unusual characteristics for 
infectious diseases (Asher, 1997). These include long, asymptomatic incubation periods in 
the range of years or decades in humans, long durations of overt clinical illness, and clinical 
manifestation as neurodegenerative conditions. Sometimes referred to as “slow viruses,” 
these disorders may be caused by conventional viruses – those more commonly associated 
with acute neurologic infectious illness. Others are caused by unconventional transmissible 
agents, in which the mechanism of pathology is less clear.
Subacute sclerosing panencephalitis—SSPE is a syndrome caused by persistent CNS 
infection with measles virus (Johnson, 1998). It is thought that various mutations in the 
infecting measles virus allow for establishment of a persistent infective state within the 
nervous system; various pathophysiologic mechanisms for this persistent infection have 
been hypothesized, but none has been proven. SSPE primarily affects children and 
adolescents, with more than 85% of cases being between 5 and 15 years of age (Gutierrez et 
al., 2010). Typically there is a history of measles rash illness with uneventful recovery; 
several years later, affected persons develop insidious onset of behavioral changes, 
neurocognitive impairment, and movement disorders followed by frank dementia; signs of 
acute encephalitis are not present. The illness is generally fairly rapidly progressive, with 
death occurring between several months and 3 years after onset, generally due to secondary 
complications.
Epidemiologic studies of SSPE suggest that males are twice as likely to develop the 
syndrome as females; cases are more common in children from rural areas than from urban 
settings (Modlin et al., 1979). There has been some evidence for geographic clustering of 
cases of SSPE, with incidence in the United States being highest in southeastern and 
midwestern states (Modlin et al., 1979). In the United States, the incidence of SSPE has 
decreased dramatically since the 1960s: the mean annual incidence of SSPE in 1960 was 
0.61 per million persons under age 20, compared with 0.06 cases per million in 1980 
(Modlin et al., 1977, 1979). This decrease in SSPE correlates with the use of live attenuated 
measles vaccine starting in 1963. Despite concerns that the attenuated measles vaccine may 
itself represent a risk for development of SSPE, the overall risk for SSPE following measles 
infection has been estimated to be 29 times greater than that following measles vaccination 
(Halsey et al., 1980). Earlier measles infection appears to carry a greater risk, with the risk 
of SSPE following measles infection before age 18 months greater than infection at older 
ages. Despite a dramatic decline in cases of SSPE in the developed world, SSPE continues 
to occur in the developing world and areas where measles vaccine is not widely used 
(Bellini et al., 2005; Campbell et al., 2007).
Progressive multifocal leukoencephalopathy (PML)—PML is a rare, progressive 
demyelinating neurologic disorder due to persistent infection with JC virus (JCV), a human 
polyomavirus (Scheld et al., 1997). Infection with JCV appears to be extremely common, 
with infection occurring in childhood, but in most individuals is asymptomatic. Estimates 
have suggested that nearly 80% of adults in the United States and Europe have antibodies to 
JCV, with seropositivity increasing during childhood. The overall pathogenesis of JCV and 
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how it leads to PML is not understood, but it is hypothesized that viremia during primary 
infection results in persistent latent infection of the kidneys and, possibly, mononuclear cells 
(Mandell et al., 2005). During periods of immunosuppression, it is thought that latent virus 
within kidney cells reactivates. Clinically, PML most often presents with progressive focal 
neurologic deficits, including hemiparesis, visual field deficits, and ataxia, as well as 
neurocognitive impairment. Most involvement is within the cerebral white matter, with 
progressive patchy or confluent demyelination. Patients generally undergo rapid 
deterioration, with death occurring within 6 months of onset. Definitive diagnosis of PML is 
based upon detection of JCV in brain tissue or CSF by polymerase chain reaction or virus 
isolation.
Prior to the emergence of HIV, PML was uncommon, occurring mostly in older individuals 
with underlying hematologic malignancies or other severe immunosuppression. In the HIV 
era, the epidemiology of PML has undergone substantial and interesting changes. 
Subsequent to the emergence of HIV, reported PML deaths rose considerably; the age-
adjusted death rate from PML in the United States increased 20-fold, from 0.2 per million 
persons in 1984 to 3.3 per million persons in 1994 (Holman et al., 1998). PML-associated 
death rates peaked in the mid-1990s, however, and subsequently there has been a decrease in 
PML-associated deaths, from 2.76 deaths per million persons in 1992–1995 to 0.66 in 2002–
2005 (Christensen et al., 2010). This decrease has corresponded to the widespread use of 
highly active antiretroviral treatment (HAART) in the treatment of HIV/acquired 
immunodeficiency syndrome (AIDS) in the United States (Clifford et al., 1999; Christensen 
et al., 2010).
Similar findings were obtained from a Swiss cohort study, which found a decrease in 
incidence rate of PML from 0.24 per 100 person-years from 1993 to 1995 to 0.06 per 100 
person-years from 1996 onward (Khanna et al., 2009). HAART also appears to have 
improved survival among persons with HIV-associated PML, with mortality decreasing to 
approximately 50% (Clifford et al., 1999). More recently, reports of PML associated with 
the use of immune-modulating monoclonal antibodies such as natalizumab to treat multiple 
sclerosis and Chron’s disease have suggested that the use of these medications may be a 
contributing risk factor (Clifford et al., 2010). Currently, it is estimated that more than half 
of deaths attributable to PML are still associated with HIV infection, however.
Creutzfeld–Jakob disease (CJD) and other prionopathies—The prionopathies 
constitute an unusual group of syndromes caused by novel infectious agents that result in 
rapidly progressive neurologic deterioration and ultimately death. The causative agent of 
these illnesses is thought to be a transmissible proteinaceous particle devoid of nucleic acid 
(a misfolded prion protein, PrPsc) (Belay, 1999; Johnson, 2005). The normal form of the 
prion protein is a normal cellular protein with an unclear function (cellular PrP, PrPc). A 
transformation of the normal prion protein into an abnormal configuration (PrPsc, see 
below) changes the physicochemical properties of the protein; the resultant aberrant protein 
is extremely resistant to typical methods of denaturation such as heat, chemical, or radiation 
exposure. This form of the protein has the capacity for self-replication; transformation of 
PrPc to PrPsc may occur sporadically but rarely, in genetically normal individuals, or the 
transformation may be facilitated and occur commonly in persons with certain genetic 
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mutations that alter the amino acid sequence of the prion protein. It is unclear how PrP 
replicates, but it has been proposed that the combination of PrPsc with a PrPc molecule 
results in the formation of a heterodimer intermediate that subsequently forms two PrPsc 
molecules; this becomes a self-perpetuating process in which exponentially increasing 
numbers of PrPc are converted to abnormal PrPsc (Hu et al., 2008). The accumulation of 
PrPsc in nervous system tissue results in neuronal damage characterized by vacuolar 
changes, resulting in a spongiform appearance of neural parenchyma at histopathology, and 
giving the prionopathies the nomenclature of “transmissible spongiform encephalopathies” 
(TSEs) (Belay, 1999).
Prionopathies may affect both animals and humans. The prototypical animal prionopathy is 
scrapie, a TSE affecting sheep and goats, from which the term PrPscrapie (PrPsc) is derived. 
Other animal TSEs include transmissible mink encephalopathy, chronic wasting disease in 
North American elk and deer, and bovine spongiform encephalopathy (BSE) in cattle 
(Sejvar et al., 2008b). Human prionopathies include kuru, fatal familial insomnia, 
Gerstman–Straussler–Scheinker syndrome, and CJD (Brown and Mastrianni, 2010).
The epidemiology of CJD is the best understood of the human prionopathies. First described 
in the early 1920s, there are several subtypes of CJD. In all subtypes, CJD generally begins 
clinically with cognitive deterioration, including dementia, behavioral problems, and other 
cortical signs (Johnson, 2005). During the course of disease, additional neurologic signs will 
develop, including myoclonus, ataxia, and extrapyramidal features. Cognitive decline is 
progressive, and although longer survival times have been reported, most patients die within 
6–9 months of diagnosis. The most common form of CJD is sporadic CJD (sCJD), in which 
by definition there is neither a mutation in the prion protein nor a clear environmental source 
of infection. sCJD is uncommon, and occurs worldwide, with an incidence of about 1 per 
million population per year in North America and Europe (Brown and Mastrianni, 2010). 
The incidence may be slightly less in Asia (Shi et al., 2008; Lu et al., 2010; Nozaki et al., 
2010), and little is known about the epidemiology of sCJD in sub-Saharan Africa. sCJD is 
an illness of advanced age, with a mean age at onset of approximately 62 years; the age-
adjusted incidence of sCJD in persons 65 years and older is approximately 5 per million per 
year. There is no gender difference; in the United States, the age-adjusted incidence of sCJD 
is 2.7 times higher in whites than blacks (Holman et al., 2010). A number of epidemiologic 
studies have been conducted to assess for possible risk factors for sCJD; however, aside 
from age and a family history of CJD, no consistent risk factors have been identified (Belay 
and Schonberger, 2005; Ward et al., 2008; Ruegger et al., 2009).
Familial CJD (fCJD) results from genetic mutations in the gene encoding the PrP (PRNP 
gene), and accounts for approximately 10% of CJD cases overall. At least 30 different 
mutations in the PRNP gene are associated with inherited prion diseases, including fCJD; 
the most common of these mutations (E200K) has been associated with geographic clusters 
of fCJD in various regions, including Slovakia, Chile, and among Jews in Greece and Israel 
(Johnson, 2005). fCJD is frequently associated with a younger age at onset. Due to its 
transmissible nature, various cases of iatrogenic CJD have occurred, through various 
mechanisms, including contaminated neurosurgical instruments, dura mater grafts, corneal 
transplant, and human pituitary hormone administration (Hamaguchi et al., 2009a). 
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Transmission through neurosurgical instruments has been based upon the high infectivity of 
neural tissue with PrPsc, and the resistance of PrPsc to typical decontamination and 
sterilization methods that would typically be used on such instruments (Hamaguchi et al., 
2009b). However, despite the millions of neurosurgeries performed each year, there have 
been only a handful of documented cases of CJD being associated with contaminated 
neurosurgical instruments or implanted electroencephalogram electrodes.
Beginning in 1995, several cases of CJD with atypical features were noted in the United 
Kingdom; these cases had illness onset at a much younger age (mean age at onset of 26 
years), a longer duration of illness before death, and atypical initial symptoms, including 
psychiatric manifestations and prominent sensory disturbances (Collinge and Rossor, 1996; 
Will et al., 1996). Early on, a link between this “new variant” CJD (now variant CJD, vCJD) 
and BSE in cattle was suspected, based upon several lines of epidemiologic and pathologic 
data, and suggested transmission of the BSE prion agent from cattle to humans (Collinge, 
1997). The BSE epidemic began in 1985, and peaked during 1992–1993, with a decline 
following the prohibition of using ruminant protein, which presumably contained BSE-
infected brain and spinal cord, as feed for other ruminants.
The identification of the first cases of vCJD in 1995 would roughly correspond to what is 
understood about the incubation period for prions. The neuropathologic features of vCJD are 
quite different from those of sCJD, and the PrPsc of vCJD has a similar mobility pattern on 
electrophoresis to that of BSE PrPsc (Bradley, 2002). These data, along with experimental 
animal inoculation studies, and the epidemiology of vCJD in relation to BSE, suggest that 
vCJD was the result of human infection with the BSE agent, with the suspected route of 
transmission being the human consumption of meat or meat products contaminated with 
neural tissue harboring the BSE agent. Presumably, exportation of either contaminated feed 
or contaminated beef products prior to implementation of the feed ban allowed for spread of 
the BSE agent outside the United Kingdom.
As of January 2011, there had been 219 cases of definite or probable vCJD reported 
worldwide from 13 countries, with the vast majority occurring within the United Kingdom 
(University of Edinburgh, 2011). As opposed to sCJD, there is evidence that the vCJD agent 
may be transmitted from person to person through blood or blood products (MacGregor and 
Prowse, 2004); this fact has led to restrictions on blood donation from persons spending 
specific periods of time in the United Kingdom. To date, the vCJD epidemic appears to have 
peaked in 1999, with a steady decline in cases since then; the future epidemiology of vCJD 
remains unknown at present, however.
Epidemiology of emerging viral neurologic diseases
By the middle of the 20th century, the impact of infectious diseases on human health was 
widely viewed to be in its final phases. The infectious disease pioneer Sir McFarland 
Burnett wrote, in 1962, “One can think of the middle of the 20th century as the end of one of 
the most important social revolutions in history – the virtual elimination of the infectious 
disease as a significant factor in social life” (Davis and Lederberg, 2001). This view had 
been bolstered by recent successes, including the worldwide eradication of smallpox, the 
development of effective antimicrobial and antiviral drugs, and dramatic improvements in 
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public health and sanitation; the possibility that infectious diseases would no longer pose a 
continued threat to humans seemed quite promising. Unfortunately, recent decades have 
seen the emergence and re-emergence of infectious diseases on a wide scale (Table 3.2). The 
emergence of HIV and AIDS in the early 1980s, the emergence of BSE and the subsequent 
breach of the species barrier to cause vCJD, and, more recently, the emergence of WNV in 
North America all serve as recent examples.
There are a number of social, cultural, and epidemiologic factors that are thought to play an 
ever-increasing role in the emergence and re-emergence of various infectious diseases 
(Davis and Lederberg, 2001):
1. Demographics—the world’s population is now estimated to increase by over 350 
000 persons per day (http://www.census.gov/cgi-bin/ipc/pcwe). In certain regions 
of the world, this population growth rate is even higher. Such population growth 
has numerous effects, including an increase in population and housing density with 
the associated breakdown in hygienic infrastructure; increased migration within and 
between populations; and encroachment of human populations upon wildlife 
habitats, increasing the chances for zoonotic transmission of infectious agents.
2. Social/behavioral changes – several aspects of human behavior directly or 
indirectly foster the emergence of infectious diseases. Sexual behavioral practices 
can lead to the spread of sexually transmitted disease (STDs), and foster the spread 
of emerging and re-emerging STDs, with HIV and the re-emergence of syphilis 
serving as prime examples. The increase in world travel, and the speed in which 
that travel may be accomplished, facilitates the spread of agents around the globe, 
as has been seen with the rapid spread of severe acute respiratory syndrome 
(SARS). Even activities such as keeping exotic pets have been linked to emerging 
zoonoses, as was seen in an outbreak of monkeypox in the midwestern United 
States.
3. Advances in healthcare – recent beneficial accomplishments in human health care 
have had implications on in factious disease emergence. Advances in chemotherapy 
and immunomodulation, while of tremendous benefit, have set the stage for a surge 
in opportunistic infections. Transplantations themselves have been associated with 
several cases of transmission of encephalitic agents, including recent cases of 
transplant-associated rabies, WNV, and lymphocytic choriomeningitis virus. 
Invasive procedures have similarly carried with them the risk of introduction of 
infectious pathogens in unusual settings.
4. Changes in treatment of water/food– as the food and agricultural industries shift 
more and more to mass-production paradigms, the potential for food-borne 
infectious disease outbreaks to occur on a large scale has increased. What in the 
past would have been limited to local out breaks of food-borne illness have now 
become multistate or multinational epidemics, leading to hundreds or thousands of 
cases of illness spread over vast geographic areas. This has been seen recently in 
outbreaks of Escherichia coli associated with salad greens, and with cases of 
bacterial infections from tainted meat products. Sometimes animal feed practices 
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have been associated with continued spread of an epidemic; the practice of feeding 
meat-and-bone meal from rendered cattle presumably infected with the BSE agent 
is thought to be the mechanism of amplification of the outbreak of mad cow disease 
in the United Kingdom.
5. Microbial evolution – the emergence of a new disease often represents natural 
evolution and change of the agent in question, leading to increased virulence in 
humans. In some cases, the use of antimicrobials leads to selection for microbes 
that are resistant to the agents, and may select for strains that have increased 
virulence. Increased antibiotic resistance among some of the more common 
pathogenic agents is likely to continue to be a problem.
6. War / natural disasters – wars and conflicts lead to a breakdown of public health 
infrastructure, increasing the likelihood of outbreaks of various diseases. Similarly, 
natural disasters may lead to similar public health breakdowns, increasing the 
likelihood of infectious disease outbreaks.
7. Deliberate release of pathogens – although biowarfare and bioterrorism have 
existed since antiquity, the potential for mass casualties due to the deliberate use of 
biologic agents in war or terrorism has grown concomitant with the dynamics and 
changing demographics of modern urban society.
Thus, there are multiple factors of modern society that, perhaps more than at any time in 
history, appear to be able to facilitate the emergence, re-emergence, and spread of infectious 
agents. In considering the neurologic manifestations of the emergence of an infectious agent, 
there are several notable examples that serve as templates for possible future occurrences.
The introduction or emergence of an infectious agent outside its endemic area
West Nile virus—The emergence of WNV in North America and its subsequent spread 
throughout the western hemisphere serve as good examples of a neurotropic human virus 
emerging in an unsuspected setting. WNV historically had been associated with infrequent 
outbreaks of mild, nonspecific febrile illness, mainly among children and young adults, in 
areas throughout Africa and the Middle East (Hayes, 1989; Solomon et al., 2000; Thakare et 
al., 2002), with several larger outbreaks occurring in Romania, Russia, and Israel in the mid- 
and late 1990s. The first relatively large outbreak of WNV with significant numbers of 
neurologic illness occurred in Romania in the summer of 1996 (Ceausu et al., 1997; 
Campbell et al., 2001); until that time, neurologic illness with WNV was infrequently 
reported. In 1998, however, a large outbreak of WNV with significant numbers of 
neurologic cases occurred in Israel (Chowers et al., 2001). In the summer of 1999, however, 
an unusual clustering of cases of encephalitis was identified in New York City; due to 
serologic testing difficulties, the outbreak was initially attributed to St. Louis encephalitis 
virus, an arbovirus closely related to WNV. However, subsequent testing identified the agent 
as WNV, the first time it had appeared in North America. Since that time, WNV has spread 
dramatically throughout North America, producing the largest consecutive outbreaks of viral 
encephalitis in the western hemisphere, with activity now reported in all 48 contiguous US 
states, and in parts of southern Canada. The epidemic peaked in 2003, and WNV activity has 
subsequently declined; however, the future epidemiologic pattern of the virus remains 
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unclear. Mosquito, avian, and equine circulation has also been seen in the Caribbean and in 
Central and South America. As of January 2011, there have been over 30 000 human cases 
in the United States, including >12 000 neuroinvasive disease cases and >1200 deaths.
The emergence of WNV in North America also witnessed the recognition of previously 
unrecognized modes of transmission of the virus. In 2003, cases of WNV acquired through 
blood transfusion were identified; recognition of this mode of transmission led to the rapid 
development of a screening nucleic acid amplification test allowing for the screening of all 
blood donors for WNV to minimize this risk. Also during that year, a cluster of cases of 
WNV acquired through solid-organ transplantation was identified, and since that time 
several other episodes of this mode of transmission have occurred.
Monkeypox—In 2003, an outbreak of rash illness was detected in the midwestern United 
States. The etiology of the illness was initially uncertain, but eventually was determined to 
be monkeypox, a rare viral disease occurring in central and West Africa. Monkeypox is an 
orthopoxvirus with clinical features similar to smallpox, though human disease from 
monkeypox is generally less severe and associated with lower mortality than that of 
smallpox. It is endemic in several central and West African countries, and causes human 
illness through contact with infected primates or small mammals (Parker et al., 2007). 
Traceback investigation of the outbreak in the United States determined that the virus had 
been introduced through a shipment of animals from Ghana which included monkeypox-
infected rodents (Kile et al., 2005). These African rodents, imported as exotic pets, then 
infected prairie dogs in the United States during transport and holding; humans became 
infected through contact with the infected prairie dogs. Overall, 72 cases of illness were 
reported from six midwestern states, including a young child who developed severe 
monkey-pox encephalitis (Sejvar et al., 2004). This outbreak highlighted the potential threat 
of introduction of non-indigenous pathogens from exotic animals, and illustrated the 
possible emergence of new zoonotic diseases through animal transport. As a result of this 
outbreak, new rules and guidelines regarding the shipment and sale of exotic animals have 
been drafted in the United States and Europe.
The emergence of a novel infectious agent
The description of the emergence of BSE in the United Kingdom serves as a good example 
of this type of emergence (see above). Another recent example is the emergence of Nipah 
virus in South Asia. In 1998 a large outbreak of encephalitis occurred in Malaysia, mainly 
among abattoir workers. The outbreak was quickly recognized as being associated with 
exposure to swine, and as a result the outbreak was initially attributed to JEV, an arbovirus 
in which pigs serve as intermediate hosts, and which was known to cause illness in the area. 
Subsequent laboratory testing, however, excluded JEV, and the infecting agent eventually 
was discovered to be a new paramyxovirus; this virus was closely related to the recently 
described hendraviruses, and to measles virus (Dixon et al., 1999; Bhangoo et al., 2005). 
The virus was named Nipah virus (NiV), based upon the location of its first isolation. Since 
its recognition, Nipah virus has caused outbreaks of severe encephalitis in a number of 
countries in South Asia, most notably Singapore, Indonesia, and Bangladesh (Anonymous, 
2004; Hsu et al., 2004; Bhangoo et al., 2005; Reynes et al., 2005). Nipah virus is a zoonotic 
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agent, and is transmitted to humans through exposure to secretions from animals, primarily 
pigs and bats of the Pteropus genus (Kang et al., 2003; Wacharapluesadee et al., 2005). 
Human-to-human transmission has been thought to be uncommon, but evidence from recent 
outbreaks suggests that it may occur. To date, outbreaks of Nipah virus have been infrequent 
and have remained geographically self-limited. The possible widespread transmission of this 
emerging zoonotic disease is at present unclear.
Deliberate release of an otherwise uncommon but virulent agent in an act of bioterrorism 
or biowarfare
There are multiple infectious agents, including several viruses, which have the potential to 
be used in a deliberate attack. Fortunately, in the recent past such intentional attacks have 
been infrequent. Perhaps the most notable recent event has been the anthrax attacks in the 
northeastern United States of 2001 (Jernigan et al., 2001). The greatest concern for 
weaponization of viral agents centers on variola virus, the causative agent of smallpox, 
Venezuelan equine encephalitis virus, an arbovirus of the Togavirus family, and the viral 
hemorrhagic fevers, including Ebola and Marburg viruses, filoviruses that have been 
associated with periodic outbreaks of severe hemorrhagic fever. Although the weaponization 
of these viruses remains difficult, advances in technology and human creativity 
unfortunately render this plausible.
Thus, in addition to the more typical factors influencing the epidemiology of infectious 
diseases, these various other ancillary factors influencing the emergence and re-emergence 
of novel pathogens and means of transmission are likely to continue to play an important 
and increasing role in the epidemiology of nervous system infections.
SUMMARY
The field of neurovirology will undoubtedly experience evolution and change in the years to 
come. The epidemiology of viral CNS diseases continues to change, and as our 
understanding of the pathogenesis and pathophysiology associated with viral agents grows, 
so does our understanding of the behavior of these pathogens among populations. The 
appearance of viral pathogens in new settings, new or unrecognized modes of transmission, 
and the emergence of previously unrecognized pathogens will continue to challenge our 
laboratory diagnostic and epidemiologic capabilities. However, each lesson that is learned 
from this evolving epidemiology will hopefully result in improved surveillance, diagnostic, 
and treatment and prevention capabilities.
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Example of an epidemiologic curve, demonstrating the pattern of a point-source outbreak 
with a single incubation period.
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Global incidence of poliomyelitis, reported as virologically confirmed cases of paralytic 
poliomyelitis, from 1980 to 2009. Cases for 2000–2009 have been replotted in inset to 
demonstrate recent increase. (Reproduced from Nathanson and Kew (2010), with 
permission.)
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Common causes, distribution, and epidemiology of viral neurologic infections
Virus Distribution, epidemiology Clinical neurologic manifestations
Adenoviruses Worldwide, sporadic Uncommon cause of meningitis, encephalitis,
anterior myelitis; sometimes associated with





Worldwide, sporadic Uncommon cause of meningitis / encephalitis, mainly
in immunosuppressed individuals
“New world”* South America, sporadic
with epidemics
Primarily results in hemorrhagic fever; may
occasionally result in encephalitis
Cytomegalovirus Worldwide, sporadic Associated with several neurologic manifestations,
including congenital neurodevelopmental disorders,
meningitis, encephalitis, polyradiculitis; association
with Guillain–Barré syndrome; illness associated
with immunosuppression
Enteroviruses Worldwide, endemic with
occasional large epidemics
Multiple different serotypes; common causes of
aseptic meningitis worldwide. Occasional cause of
encephalitis, anterior myelitis, particularly in the
setting of large epidemics
Poliovirus† Africa, Asia, endemic with
epidemics
Most common cause of anterior myelitis; eradicated in
the western hemisphere, but continued epidemic
disease in several African and Asian countries; may
result in meningitis, encephalitis
Epstein–Barr virus Worldwide, sporadic Occasional cause of meningitis, encephalitis;
association with Guillain–Barré syndrome, brachial
plexopathy; associated with primary central nervous
system lymphoma
Hendra virus Australia, sporadic Recently recognized cause of severe encephalitis in
northern Australia
Herpes simplex virus (1 and 2) Worldwide, sporadic Most common cause of sporadic encephalitis with
identified etiology worldwide; can cause aseptic
meningitis, anterior myelitis, radiculomyelitis
Human herpesvirus-6 Worldwide, sporadic Occasional cause of encephalitis, particularly in
immunosuppressed individuals
Human herpesvirus-7 Worldwide, sporadic Occasional cause of encephalitis, particularly in
immunosuppressed individuals
Human immunodeficiency virus Worldwide, currently largest
epidemics in Africa, Asia
Wide range of neurologic manifestations; may include




Worldwide (higher incidence in
Japan, warmer equatorial
regions), sporadic
Neurological manifestations include tropical spastic
paraparesis (TSP), chronic HTLV-1 myelitis, and
HTLV-1-associated myelopathy (HAM)
Influenza (A, B) Worldwide, epidemic Primary illness is respiratory; may result in influenza-
associated encephalopathy (uncommon); association
with Reye syndrome
Japanese encephalitis virus Asia, Pacific; endemic with large
epidemics
Most common cause of encephalitis in Asia; may result
in meningitis, encephalitis, anterior myelitis
JC virus Worldwide, sporadic Causative agent of progressive multifocal
leukoencephalopathy (PML), resulting in
progressive demyelinating syndrome; primarily seen
in the setting of immunosuppression
Measles virus Worldwide, endemic with
epidemics
May uncommonly cause meningitis, encephalitis;
persistent infection results in subacute sclerosing
panencephalitis (SSPE)
Mumps virus Worldwide, endemic
with epidemics
May occasionally cause meningitis, less commonly,
encephalitis














Virus Distribution, epidemiology Clinical neurologic manifestations
Nipah virus South Asia, Pacific, epidemic Epidemics of encephalitis; incidence of meningitis
unknown; may result in relapsing neurologic disease
Rabies virus Worldwide, endemic Cause of severe, fatal encephalitis; rare in developed
world, still common in developing world; less
commonly, may produce a paralytic illness without
encephalitis
Rotavirus Worldwide, endemic Uncommon cause of meningitis, encephalitis in
children
Rubella virus Worldwide, endemic with
epidemics
May cause congenital neurologic disease; uncommon
cause of meningitis, encephalitis; rare cases of
progressive rubella panencephalitis
Tick-borne encephalitis virus Europe, Asia, North America;
endemic
Important cause of meningitis, encephalitis in central
Europe; uncommon cause of illness in other endemic
areas
Varicella-zoster virus Worldwide, endemic May cause meningitis, encephalitis, cerebellitis,
anterior myelitis. Associated with granulomatous
arteritis. Reactivation may produce ganglionitis,
radiculitis (shingles), postherpetic neuralgia
West Nile virus The Americas, Europe, Middle
East, Africa, endemic with
epidemics
Most common cause of epidemic encephalitis in North
America; may result in meningitis, encephalitis,
anterior myelitis
Other epidemiologically important arboviruses
Togaviruses




Americas, epidemics Currently rarely reported cause of sporadic and
epidemic encephalitis in North America
Venezuelan equine encephalitis
virus
Americas, epidemics Cause of epidemic encephalitis in Central and South
America
Chikungunya virus Africa, Asia, Pacific, epidemics Recent emergence and geographic spread; associated
with febrile illness/arthritic features, but occasional
association with encephalitis
Flaviviruses
St. Louis encephalitis virus Americas, epidemics Cause of seasonal sporadic cases of encephalitis with
occasional large epidemics
Murray Valley encephalitis virus Australia Important cause of epidemic encephalitis in Australia
Bunyaviridae





North America, Europe, Asia Cause of seasonal sporadic cases of encephalitis;
occasional geographically limited epidemics
*
Includes Junin, Machupo, Guanarito, Sabia viruses.
†
Poliovirus included as a separate subset of enterovirus.
Terminology:
Sporadic: Resulting in occasional cases of illness on an irregular and unpredictable pattern.
Endemic: Prevalent or persistently present in population, regularly causing illness.
Epidemic: Affecting large numbers of persons in a geographic area over a particular time period, above expected rates.















Emerging and re-emerging infectious diseases worldwide since 1980. Viral infectious diseases and 
prionopathies are given in bold text
Year Natural epidemics Intentional release
1981 Human immunodeficiency virus (worldwide)
1982 Lyme disease (neuroborrreliosis) (northeastern
United States)
1984 Cryptosporidiosis (Texas, NM) Salmonella (salad bars,
United States)
1985 −86 Bovine spongiform encephalopathy emerges
(United Kingdom)
1987 Multidrug-resistant tuberculosis (US prisons)
1991 Guanarito virus (Venezuela)
1992 Vibrio cholerae 0:139 (India)
1993 Escherichia coli O:157:H7 (United States)
Hantavirus pulmonary syndrome (southwestern
United States)
1994 Variant Creutzfeldt–Jakob disease
(United Kingdom)
Hendra virus (Australia)
1995 Recurrence of Ebola hemorrhagic fever
(Democratic Republic of the Congo)
1996 Poliovirus vaccine virus reversion to
neurovirulent strain (Dominican Republic)
Shigella (baked goods,
United States)




1998 Nipah virus encephalitis (Malaysia)
1999 West Nile virus (New York City)
2000 Rift Valley fever (Yemen, Saudi Arabia)
2001 Anthrax (US postal
facilities, Eastern
United States)
2002 Severe acute respiratory syndrome (SARS)
(Asia, Canada)
2003 Monkeypox (midwestern United States)
2004 Marburg hemorrhagic fever (Angola)
Nipah virus (Bangladesh)
2005 Multidrug-resistant Salmonella (United States,
pet rodents)
2006 E. coli (salad greens, multiple US states)
2007 Rift Valley fever (Kenya)
2009 Salmonella typhi with neurologic illness
(Malawi/Mozambique)
Influenza A H1N1 (worldwide)
2010 Vibrio cholerae (Haiti)
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